Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mail: <u>info@amphray.com</u> Website: <u>www.triochemproducts.com</u> Corporate Identity Number: L24249MH1972PLC015544



Ref No: TPL PP 20231238 2023; 9th February 2024

To BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai: 400 001.

Security Code No. 512101 - ISIN No.: INE331E01013.

Dear Sir / Madam,

<u>Sub:</u> Submission of Unaudited Standalone Financial Results for the quarter and nine months ended 31st December 2023

We refer to our letter dated 31st January 2024 on the captioned subject.

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions, if any. In this subject, we wish to inform you that the Board of Director of the Company at its meeting held today i.e. Friday, 9th February, 2024 have inter-alia considered and approved the Unaudited Standalone Financial Results for the quarter and nine months ended 31st December 2023 duly reviewed by the Audit Committee along with Limited Review Report submitted by the Statutory Auditors of the Company are enclosed for your perusal and records.

The said financial results, duly signed by the Mr. Ramu S. Deora, Director was the Chairperson of the Board meeting held on 9^{th} February 2024 and the authorized director to sign and submit the Said Financial Result to the Bombay Stock Exchange. Therefore, the company is in compliance of the Regulation 33(2)(b) of the SEBI (LODR), Regulation 2015.

Also, informed that the unaudited financial results in prescribed format will be published in "Free Press Journal" and "Navshakti" newspaper, as required. Please take the same in you record.

Thanking you, Yours faithfully, For **TRIOCHEM PRODUCTS LIMITED**

RAMU S. DEORA DIRECTOR DIN: 00312369 Encl.: as above



Kanu Doshi Associates LLP

Chartered Accountants

Mumbai Office : 203, The Summit, Hanuman Road, Western Express Highway, Vile Parle (E), Mumbai - 400 057 •T : 022-2615 0100

Pune Office : 109, Sohrab Hall, 21 Sassoon Road, Opp. Jehangir Hospital, Pune - 411001 • T : 020-4906 7177

• E : info@kdg.co.in • W : www.kdg.co.in

Independent Auditor's Review Report on Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

The Board of Directors of TRIOCHEM PRODUCTS LIMITED ("Company")

- We have reviewed the accompanying statement of unaudited financial results of TRIOCHEM PRODUCTS LIMITED ("Company") for the quarter and nine months ended December 31, 2023 being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by SEBI from time to time.
- 2. The statement is the responsibility of the Company's management and has been approved by Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind As 34"), specified under Section 133 of the Companies Act, 2013, SEBI Circular CIR/CFD/PAC/62/2016 dated 5 July 2016 (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India.
- 3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limitedprimarily to inquiries of company personnel and an analytical procedure applied to financialdata and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kanu Doshi Associates LLP Chartered Accountants Firm Registration No: 104746W/W100096

Kunal Vakharia Partner Membership No: 148916 UDIN: 241489166KCQ KA451 Place: Mumbai Date: February 9, 2024

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS



Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, <u>PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657</u>

E-mall: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544

TRIOCHEM PRODUCTS LIMITED

Registered Office : Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai • 400 001.

Website: www.triochemproducts.com

CIN: L24249MH1972PLC015544

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023

Sr.			Quarter Ender	1	(Rs in Lakh) Except EPS Nine Months Ended Year Ended			
NO.		31-Dec-23 30-Sep-23		31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23	
110.		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1 I	income							
0	(a) Revenue from Operations							
0	(b) Other Income	3.50	5.49	3.08	22.73	20.54	27.75	
1	Fotal Income From Operations	3.50	5.49	3.08	22.73	20.54	27.75	
2 F	Expenses							
0	a) Cost of Materials Consumed	•			•		-	
(b) Purchase of stock in trade	•		-	•	•	•	
	(c) Changes in inventories of finished goods, work-in- progress and stock-in-trade		·	•		•	•	
0	d) Employees Benefit Expenses	11.23	11.61	13.60	34.20	39.00	52.28	
0	e) Finance Costs			•			-	
0	f) Depreciation and Amortisation Expenses	2.26	2.26	2.65	6.76	7.91	10.50	
0	g) Other Expenditure	11.83	17.90	19.71	44.12	64.18	81.96	
T	fotal expenses	25.32	31.77	35.96	85.08	111.09	144.74	
3 P	Profit before exceptional items and tax	(21.82)	(26.28)	(32.88)	(62.35)	(90.55)	(116.99)	
4 E	Exceptional items (refer Note 4)		(115.65)	-	(115.65)	-		
5 P	Profit/ (Loss) before tax	(21.82)	(141.93)	(32.88)	(178.00)	(90.55)	(116.99)	
6 T	ax Expense							
(a) Current tax			0.05		(0.80)	(0.85)	
0	b) Deferred tax	(1.38)	(39.39)	(8.16)	(44.23)	(21.12)	(27.63)	
T	'otal tax expenses	(1.38)	(39.39)	(8.11)	(44.23)	(21.92)	(28.48)	
7 N	let Profit/ (Loss) for the period	(20.44)	(102.54)	(24.77)	(133.77)	(68.63)	(88.51)	
8 0)ther Comprehensive Income (Net of Taxes)							
0	A)(i). Items that will be reclassified to profit or loss		•		.	-		
	(ii). Income tax relating to items that will be reclassified profit or loss			-	-	-	•	
(1	B)(i). Item that will not be reclassified to profit or loss	214.88	65.17	55.32	358.07	17.61	(63.71)	
1	(ii). Income tax relating to items that will not be eclassified to profit or loss	(24.62)	(7.38)	(2.10)	(40.96)	(2.00)	7.28	
T	otal other Comprehensive Income (net of taxes)	190.26	57.79	53.22	317.11	15.61	(56.43)	
T	otal Comprehensive Income for the period	169.82	(44.75)	28.45	183.34	(53.02)	(144.94)	
	aid-up equity share capital (Face Value of ₹ 10/- per	24.50	24.50	24.50	24.50	24.50	24.50	
2 Ea	ther equity as per Balance Sheet of previous accounting yearnings per equity share (EPS) (of Rs. 10/- each) (not nualised)	ar					1,135.22	
	asic / Diluted EPS (in Rs.)	(8.34)	(41.85)	(10.11)	(54.60)	(28.01)	(36.13)	



4



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS



Registered Office: 4th Floor, Sambava Chambers, Str. P. M. Road, Fort, Mumbai, Maharashtra, <u>PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657</u> E-mall: info@amphray.com Website: www.triochemproducts.com.

Corporate Identity Number: L24249MH1972PLC015544

TRIOCHEM PRODUCTS LIMITED Registered Office : Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001. Website: www.triochemproducts.com CIN: L24249MH1972PLC015544 STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023 Notes: 1) The above standalone unaudited financial results of the Company for the guarter and nine months ended 31st December 2023 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 09.02.2024. The same have been reviewed by the Statutory Auditors who have issued an unqualified conclusion thereon 2) The Unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India., as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI). 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals, therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable. 4) During the period, the company has comply with circular no. 16/2023-Cus dated 7th June 2023 issud by The Central Board of Indirect taxes and Customs Drawback division for compliance with the pre-import condition for payment of IGST and interest thereon for imports made under Advance Authorization on or after 13th October 2017 till 9th January 2019 on which IGST exemption had been availed. As per the circular the company was non-compliant with the 'pre-import' conditions as defined in the revised circular no. 16/2023-Cus dated 7th June 2023 due to which the company was liable to pay Rs 259.87 lakhs including interest. The Company has claimed the credit of IGST paid and the interest portion amounting to Rs. 115.65 lakhs has been shown under Exceptional items. 5) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary FOR TRIOCHEM PRODUCTS LIMITED RAMU S. DEORA CHAIRPERSON Place: Mumbai DIN: 00312369 Dated: 9th February, 2024





MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS



Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, <u>PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657</u>

E-mall: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: 124249MH1972PLC015544

TRIOCHEM PRODUCTS LIMITED Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001 website: www.triochemproducts.com

CIN: L24249MIH1972PLC015544

(Rs. in lakhs) Except EPS

						(in the second	ino) anocpr are
EXT	RACT OF STATEMENT OF STANDALONE UNAUDITED FINANCIAL R	ESULTS FOR T	THE QUARTER	AND NINE MC	NTHS ENDED	31ST DECEM	BER, 2023
Sr	Particulars	Quarter Ended			Half Year Ended		For the Year
No		31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	Ended on 31-Mar-23
		1	Total Income from operations	3.50	5.49	3.08	22.73
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	(21.82)	(26.28)	(32.88)	(62.35)	(90.55)	(116.99)
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	(21.82)	(141.93)	(32.88)	(178.00)	(90.55)	(116.99)
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	(20.44)	(102.54)	(24.77)	(133.77)	(68.63)	(88.51)
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	190.26	57.79	53.22	317.11	15.61	(56.43)
6	Equity share capital (Face value Rs.10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50
7	Other Equity						1,135.22
	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)						
	a) Basic (not annualized)	(8.34)	(41.85)	(10.11)	(54.60)	(28.01)	(36.13)
	b) Diluted (not annualized)	(8.34)	(41.85)	(10.11)	(54.60)	(28.01)	(36.13)

Notes

 The above standalone unaudited financial results of the Company for the quarter and nine months ended 31st December 2023 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 09.02.2024. The same have been reviewed by the Statutory Auditors who have issued an unqualified conclusion thereon.

2) The Unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India., as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).

3) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.

4) During the period, the company has comply with circular no. 16/2023-Cus dated 7th June 2023 issud by The Central Board of Indirect taxes and Customs Drawback division for compliance with the pre-import condition for payment of IGST and interest thereon for imports made under Advance Authorization on or after 13th October 2017 till 9th January 2019 on which IGST exemption had been availed. As per the circular the company was non-compliant with the 'pre-import' conditions as defined in the revised circular no. 16/2023-Cus dated 7th June 2023 due to which the company was liable to pay Rs. 259.87 lakhs including interest. The Company has claimed the credit of IGST paid and the interest portion amounting to Rs. 115.65 lakhs has been shown under Exceptional items.

5) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.
6) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other

Disclosure Requirements) Regulation, 2015. The full format of consolidated financial results are available on the Stock Exchange website, www.bseindia.com and on the Company's website www.triochemproducts.com

FOR TRIOCHEM PRODUCTS LIMITED

Place: Mumbai Dated: 9th February, 2024





RAMU S. DEORA CHAIRPERSON